Furthermore, elevated levels of PD-L1 expression following PTEN knockdown results in decreased proliferation and increased apoptosis in activated T cells and raise the possibility that targeting the PI3K/mTOR pathway as a therapeutic strategy may augment adaptive immune responses against cancer (88). This evidence concerns the gene PTEN and cancer.